Article Link: FDA Approves New Indication for Envarsus XR (tacrolimus extended-release tablets) COPENHAGEN, Denmark, Dec. 19, 2018 /PRNew...
FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)
Article Link: FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC) Cambridge, Mass. – December 17,...
FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
Article Link: FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin INCHEON, South Korea & JERUSALEM–(BUSINESS WIR...
FDA Approves Tolsura (SUBA®-itraconazole capsules) for the Treatment of Certain Fungal Infections
Article Link: FDA Approves Tolsura (SUBA®-itraconazole capsules) for the Treatment of Certain Fungal Infections ADELAIDE, Australia, Dec....
FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Article Link: FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of Metastatic Non-Squamous Non...
FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery
Article Link: FDA Approves Dextenza (dexamethasone ophthalmic insert) for the Treatment of Ocular Pain Following Ophthalmic Surgery BEDFO...
FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome
Article Link: FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome November 28, 2018 — The U.S. Food and Dru...
FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation
Article Link: FDA Approves Xospata (gilteritinib) for Acute Myeloid Leukemia (AML) with a FLT3 Mutation November 28, 2018 — The U.S...
FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin’s Lymphoma
Article Link: FDA Approves Truxima (rituximab-abbs), a Biosimilar to Rituxan for Non-Hodgkin’s Lymphoma November 28, 2018 — The U.S...
FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers
Article Link: FDA Approves Vitrakvi (larotrectinib) for TRK Fusion Cancers November 26, 2018 — The U.S. Food and Drug Administratio...
